J&J; to Reimburse Amgen’s Expenses
- Share via
Johnson & Johnson said Friday that a federal arbitrator ordered it to reimburse archrival Amgen Inc. for attorneys’ fees and expenses incurred by the Thousand Oaks-based biotechnology company in its drug licensing dispute. Neither side provided an estimate for the fees, but a source said they would be in the tens of millions.
In October, an arbitrator ordered J&J; to pay Amgen $150 million in damages for poaching its rival’s dialysis business. But J&J; wanted Amgen to pay for attorneys’ fees because the arbitrator denied Amgen’s request to terminate the 1985 licensing deal.
The contract permits J&J; to sell the anemia treatment EPO outside the kidney dialysis market in the United States, where Amgen exclusively sells the drug it invented.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
